Next Article in Journal
Sorafenib-Regorafenib Sequential Therapy in Japanese Patients with Unresectable Hepatocellular Carcinoma—Relative Dose Intensity and Post-Regorafenib Therapies in Real World Practice
Next Article in Special Issue
Virotherapy as a Potential Therapeutic Approach for the Treatment of Aggressive Thyroid Cancer
Previous Article in Journal
Gene-Specific Targeting of DNA Methylation in the Mammalian Genome
Previous Article in Special Issue
Thyroid Cancer after Exposure to Radioiodine in Childhood and Adolescence: 131I-Related Risk and the Role of Selected Host and Environmental Factors
Open AccessArticle

Epidemiology of Simultaneous Medullary and Papillary Thyroid Carcinomas (MTC/PTC): An Italian Multicenter Study

by Marialuisa Appetecchia 1,*, Rosa Lauretta 1, Agnese Barnabei 1, Letizia Pieruzzi 2, Irene Terrenato 3, Elisabetta Cavedon 4, Caterina Mian 4, Maria Grazia Castagna 5 and Rossella Elisei 2,† on behalf of the SIE (Italian Society of Endocrinology) Working Group
Oncological Endocrinology Unit, IRCCS Regina Elena National Cancer Institute, 00144 Rome, Italy
Endocrinology Unit, University Hospital of Pisa, 56121 Pisa, Italy
Biostatistics-Scientific Direction, IRCSS Regina Elena National Institute, 00144 Rome, Italy
Istituto Oncologico Veneto, University of Padua, 35100 Padua, Italy
Endocrinology Unit, Policlinico S.M. alle Scotte, 53100 Siena, Italy
Author to whom correspondence should be addressed.
Listed in Appendix A.
Cancers 2019, 11(10), 1516;
Received: 11 September 2019 / Accepted: 25 September 2019 / Published: 9 October 2019
(This article belongs to the Special Issue Thyroid Cancer)
Background: The concomitant presence of papillary thyroid cancer (PTC) and medullary TC (MTC) is rare. In this multicentric study, we documented the epidemiological characteristics, disease conditions and clinical outcome of patients with simultaneous MTC/PTC. Methods: We collected data of patients with concomitant MTC/PTC at 14 Italian referral centers. Results: In total, 183 patients were enrolled. Diagnosis was mostly based on cytological examination (n = 58, 32%). At diagnosis, in the majority of cases, both PTC (n = 142, 78%) and MTC (n = 100, 54%) were at stage I. However, more cases of stage II–IV were reported with MTC (stage IV: n = 27, 15%) compared with PTC (n = 9, 5%). Information on survival was available for 165 patients: 109 patients (66%) were disease-free for both PTC and MTC at the last follow-up. Six patients died from MTC. Median time to progression was 123 months (95% confidence interval (CI): 89.3–156.7 months). Overall, 45% of patients were disease-free after >10 years from diagnosis (125 months); this figure was 72.5% for PTC and 51.1% for MTC. Conclusions: When MTC and PTC are concurrent, the priority should be given to the management of MTC since this entity appears associated with the most severe impact on prognosis. View Full-Text
Keywords: medullary thyroid cancer; papillary thyroid cancer; epidemiology medullary thyroid cancer; papillary thyroid cancer; epidemiology
Show Figures

Figure 1

MDPI and ACS Style

Appetecchia, M.; Lauretta, R.; Barnabei, A.; Pieruzzi, L.; Terrenato, I.; Cavedon, E.; Mian, C.; Castagna, M.G.; Elisei, R., on behalf of the SIE (Italian Society of Endocrinology) Working Group; Epidemiology of Simultaneous Medullary and Papillary Thyroid Carcinomas (MTC/PTC): An Italian Multicenter Study. Cancers 2019, 11, 1516.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

Back to TopTop